» OSE Immunotherapeutics: Laurence de Schoulepnikoff appointed Chief Business Officer MyPharma Editions

Posted on Tuesday, December 21, 2021

OSE Immunotherapeutics announced the appointment of Laurence de Schoulepnikoff as Chief Business Officer (CBO) and the appointment of senior directors to join OSE Immunotherapeutics’ development team.

Laurence de Schoulepnikoff is a seasoned executive with over 25 years of experience and extensive expertise in business development and transactions within the pharmaceutical industry, particularly in licensing and divestiture/acquisition negotiations. Prior to joining OSE, Laurence worked at AMAL Therapeutics, a Swiss biotechnology company specializing in therapeutic cancer vaccines (acquired by Boehringer Ingelheim in 2019), where she spent 3 years as Chief Operating Officer and Chief Business Officer

Previously, Laurence worked in medium-sized companies (Ferring International, Stragen Pharma SA) and in large organizations (Business Development at Novartis).

Laurence holds a Masters in Chemical Engineering from the Ecole Polytechnique Fédérale de Lausanne (EPFL) and is a member of the Board of Directors of the Swiss Healthcare Licensing Group (HLG).

Alexis Peyroles, CEO of OSE Immunotherapeutics, commented: “I am delighted to welcome Laurence, who will come to support the company’s evolution and lead our business development and alliance management teams. His leadership skills, his recent transaction experience with an innovative cancer vaccine and his expertise in pharmaceutical licensing will undeniably provide us with new opportunities to increase our collaborative activities, a constant driver of our growth.”

OSE Immunotherapeutics is also pleased to announce the appointment of three senior directors to strengthen its development team and help advance its diverse product portfolio. Linda Lebon is appointed as Director of Regulatory Affairs, Silvia Comis as Director of Clinical Development and Françoise Bono as Director of Strategic Development.

“We are delighted to deploy our industry-leading development team with acquired international expertise in immuno-oncology and inflammation,” said Dominique Costantini, President of OSE Immunotherapeutics. “At a time when preclinical and clinical development of several of our premium products is booming, Linda, Silvia and Françoise will help effectively accelerate the advancement of our clinical resources addressing unmet medical needs. the Company at a critical moment in its evolution”.

Linda Lebon has 25 years of extensive expertise in regulatory strategy, from early development to drug approval. She has held international management positions in biotech (ArgenX), pharmaceutical (BMS, GSK Vaccines, Pfizer Animal Health) and consulting (IQVIA, Voisin Consulting Life Sciences) companies. Linda holds an MBA from the HEC School of Management and an Aggregation in Sciences from the University of Liège (Belgium) in Cellular and Molecular Biology.

Silvia Comis benefits from 30 years of international experience and leadership in the pharmaceutical industry, with strong expertise in clinical research and drug development and medical affairs, with concrete results in oncology, hematology and immuno-oncology. Silvia was most recently Senior Medical Director at IQVIA and European Head of Early Products, Medical Affairs in Oncology at Novartis, where she was involved in all clinical innovation programs in immuno-oncology. Silvia is a physician, endocrinologist and pharmacologist at the University of Pavia (Italy).

Francoise Bono has over 25 years of experience in the pharmaceutical industry in the fields of oncology, immuno-inflammation and cardiovascular. She has extensive experience in science, team management and evaluation, translational and drug development strategies. At Sanofi and then Evotec, Françoise led several innovative projects, from preclinical to translational and clinical development. Françoise holds a PhD in cellular biology from the University of Toulouse.

Source and Visual: OSE Immunotherapeutics

Leave a Comment